These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 3195405

  • 1. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O.
    Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
    [Abstract] [Full Text] [Related]

  • 2. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S, Nakano M, Matsuzaki M, Watanabe J, Morikawa H, Murata H, Oda H, Komatsu H.
    Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
    [Abstract] [Full Text] [Related]

  • 3. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S, Matsuzaki M, Morikawa H, Nakano M, Komatsu H.
    Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
    [Abstract] [Full Text] [Related]

  • 4. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A, Flex D, Gafni D, Rabinovitz O, Sulkes A, Baniel J.
    Harefuah; 1999 Feb 15; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [Abstract] [Full Text] [Related]

  • 5. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.
    Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T.
    Jpn J Clin Oncol; 1993 Oct 15; 23(5):291-8. PubMed ID: 7693990
    [Abstract] [Full Text] [Related]

  • 7. [Clinical studies of chemotherapy for patients with a solitary kidney after nephroureterectomy for advanced upper urothelial transitional cell carcinoma].
    Tsujimura A, Takayama H, Tsukikawa M, Imazu T, Sugao H, Takaha M.
    Hinyokika Kiyo; 1995 Mar 15; 41(3):183-9. PubMed ID: 7741070
    [Abstract] [Full Text] [Related]

  • 8. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S, Kubota Y, Shuin T, Masuda M, Misaki H, Yao M, Kondoh K, Sakuramoto T, Hosaka M.
    Hinyokika Kiyo; 1994 Aug 15; 40(8):677-82. PubMed ID: 7942364
    [Abstract] [Full Text] [Related]

  • 9. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A, Gotoh A, Hara I, Gohji K, Ogawa T, Arakawa S, Matsumoto O, Kamidono S, Hamami G, Itani A.
    Gan To Kagaku Ryoho; 1990 Sep 15; 17(9):1909-15. PubMed ID: 2393308
    [Abstract] [Full Text] [Related]

  • 10. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H, Okamura K, Takashi M, Shimoji T, Miyake K.
    Hinyokika Kiyo; 1997 Feb 15; 43(2):89-96. PubMed ID: 9086342
    [Abstract] [Full Text] [Related]

  • 11. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
    Yamada Y, Itoh Y, Aoki S, Nakamura K, Taki T, Naruse K, Tobiume M, Zennami K, Katsuda R, Kato Y, Watanabe M, Nishikawa G, Minami M, Nakahira M, Ukai S, Sawada M, Kitamura A, Honda N.
    Cancer Chemother Pharmacol; 2009 Nov 15; 64(6):1079-83. PubMed ID: 19277660
    [Abstract] [Full Text] [Related]

  • 12. [Early clinical result of modified M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of renal pelvis and ureter].
    Shishido S, Hayakawa M, Higa I, Koyama Y, Hatano T, Osawa A.
    Hinyokika Kiyo; 1990 Apr 15; 36(4):401-5. PubMed ID: 2378303
    [Abstract] [Full Text] [Related]

  • 13. [M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma].
    Igawa M, Ueki T, Ueda M, Okada K, Usui T, Ohnishi Y, Kume T, Masu C, Ishino T, Nakatsu H.
    Gan To Kagaku Ryoho; 1989 Aug 15; 16(8 Pt 1):2577-82. PubMed ID: 2673046
    [Abstract] [Full Text] [Related]

  • 14. [Combination chemotherapy of methotrexate, etoposide, adriamycin and cisplatin (M-EAP) for advanced urothelial cancer].
    Hashimura T, Okumura K, Akao T, Nakagawa T.
    Hinyokika Kiyo; 1991 Jul 15; 37(7):685-8. PubMed ID: 1927767
    [Abstract] [Full Text] [Related]

  • 15. [Complete remission of brain metastasis of bladder cancer treated by M-VAC therapy].
    Nakagawa S, Nakao M, Toyoda K, Nukui M, Takada H, Ebisui K.
    Hinyokika Kiyo; 1989 Feb 15; 35(2):333-5. PubMed ID: 2735244
    [Abstract] [Full Text] [Related]

  • 16. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
    Balbay MD, Ozen H, Uluçay S, Sahin A, Ergen A, Koçal C, Remzi D.
    Int Urol Nephrol; 1993 Feb 15; 25(4):351-7. PubMed ID: 8276565
    [Abstract] [Full Text] [Related]

  • 17. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
    Seguchi T, Nakano E, Miki T, Kondoh M, Nishimura K, Nakamura N, Okuyama A.
    Gan To Kagaku Ryoho; 1994 Jan 15; 21(1):59-65. PubMed ID: 8291917
    [Abstract] [Full Text] [Related]

  • 18. [Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
    Rassweiler J, Rüther U, Bäuerle K, Bub P, Jipp P, Eisenberger F.
    Urologe A; 1989 Jan 15; 28(1):25-30. PubMed ID: 2922897
    [Abstract] [Full Text] [Related]

  • 19. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
    Mikami K, Nakagawa S, Takada H, Ebisui K, Sugimoto K, Watanabe H, Maegawa M, Nakao M.
    Hinyokika Kiyo; 1994 Apr 15; 40(4):303-7. PubMed ID: 8191968
    [Abstract] [Full Text] [Related]

  • 20. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
    Stöckle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R.
    Ann Urol (Paris); 1993 Apr 15; 27(1):51-7. PubMed ID: 7682388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.